Gene · 4070
Papers3,230
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
541 to 560 of 3,230
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| [Trop-2 expression in solid tumors : Expanded protein diagnostics within the molecular tumor board]. | Pathologie (Heidelb) | 2025 | 40579477 | PubTator, text mining | PubMed |
| Correlation of TROP2 expression with clinico-pathological features and outcomes in HR+/HER2- breast cancer receiving neoadjuvant chemotherapy. | Oncologist | 2025 | 40579360 | PubTator, text mining | PubMed |
| Co-expression of tissue factor, TROP2, and NECTIN4 in primary and matched metastatic cervical cancer lesions. | Transl Oncol | 2025 | 40577962 | PubTator, text mining | PubMed |
| Emerging Concepts of Targeted Protein Degrader Technologies via Lysosomal Pathways. | Int J Mol Sci | 2025 | 40565046 | PubTator, text mining | PubMed |
| A phase 2 study of sacituzumab govitecan with or without atezolizumab in rare genitourinary tumors (SMART) - design and rationale. | Future Oncol | 2025 | 40548513 | PubTator, text mining | PubMed |
| TROP2 is highly expressed in cutaneous squamous cell carcinomas and a subset of adnexal carcinomas: A potential therapeutic target with TROP2-directed antibody drug conjugates. | Hum Pathol | 2025 | 40523445 | PubTator, text mining | PubMed |
| The complex interplay of TROP2 and PD-L1 in immune regulation and drug resistance in lung cancer. | Am J Cancer Res | 2025 | 40520853 | PubTator, text mining | PubMed |
| Integrative transcriptomics and single-cell transcriptomics analyses reveal potential biomarkers and mechanisms of action in papillary thyroid carcinoma. | Front Genet | 2025 | 40520228 | PubTator, text mining | PubMed |
| Evolution of TROP2: Biological insights and clinical applications. | Eur J Med Chem | 2025 | 40517574 | PubTator, text mining | PubMed |
| Trop-2 expression as a biomarker of response to sacituzumab govitecan in patients with HER2-negative metastatic breast cancer: A pilot study. | Cancer Treat Res Commun | 2025 | 40516178 | PubTator, text mining | PubMed |
| Advances in targeted therapy for triple-negative breast cancer: a review of key antigens and recent advances. | J Drug Target | 2025 | 40515614 | PubTator, text mining | PubMed |
| An evaluation of datopotamab deruxtecan for the treatment of non-small cell lung cancer. | Expert Opin Biol Ther | 2025 | 40515573 | PubTator, text mining | PubMed |
| Exploring the therapeutic use and outcome of antibody-drug conjugates in ovarian cancer treatment. | Oncogene | 2025 | 40514426 | PubTator, text mining | PubMed |
| COGNITION-GUIDE - Genomics-Guided Targeted Post-Neoadjuvant Therapy in Patients with Early Breast Cancer: Study Design of a Multicenter, Open-Label, Umbrella Phase II Study. | Geburtshilfe Frauenheilkd | 2025 | 40510401 | PubTator, text mining | PubMed |
| The Antibody-Drug Conjugate Sacituzumab Govitecan (IMMU-132) Represents a Potential Novel Therapeutic Strategy in Cholangiocarcinoma. | Mol Cancer Ther | 2025 | 40509933 | PubTator, text mining | PubMed |
| Personalized Treatment in Ovarian Cancer: A Review of Disease Monitoring, Biomarker Expression, and Targeted Treatments for Advanced, Recurrent Ovarian Cancers. | Cancers (Basel) | 2025 | 40507303 | PubTator, text mining | PubMed |
Efficacy and Safety of TROP-2-Targeting Antibody-Drug Conjugate Treatment in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer: A Systematic Review and Pooled Analysis of Reconstructed Patient Data. | Cancers (Basel) | 2025 | 40507234 | PubTator, text mining | PubMed |
| Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies. | J Hematol Oncol | 2025 | 40481574 | PubTator, text mining | PubMed |
| From biomarker to targeted therapy: investigating trophoblast cell-surface antigen 2 expression in triple-negative breast cancer- insights from the national cancer institute. | BMC Cancer | 2025 | 40474193 | PubTator, text mining | PubMed |
| Evaluation of sacituzumab govitecan for advanced/metastatic non-small cell lung cancer. | Expert Rev Anticancer Ther | 2025 | 40458070 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4070/papers?page=28